A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting · Phase 1 · NCT05650632
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $2.2M
- U.S. investigators named
- 21
- Sites paid
- 20
- Planned or actual enrollment
- 210
About the trial
- Sponsor
- AbbVie
- Tested
- Etentamig (ABBV-383) (drug)
- Dates
- Started 2023-03-21; completion 2029-08
- Results posted
- Not yet
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B…
From ClinicalTrials.gov, last updated 2026-07-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2.2M in research payments for this study in 2025 (217 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Muhamed Baljevic, M.D. Hematology · Little Rock, AR
- Patrick M. Travis, M.D. General Practice · Springdale, AR
- Saurabh Chhabra, M.D. Hematology & Oncology · Scottsdale, AZ
- John M. Burke, MD Hematology & Oncology · Aurora, CO
- Srilata Gundala, M.D. Hematology & Oncology · Hinsdale, IL
- Sunil Babu, M.D. Medical Oncology · Fort Wayne, IN
- Stefan C. Grant, M.D. Hematology & Oncology · New Orleans, LA
- Shaji K. Kumar, M.D. Hematology · Rochester, MN
- Eben I. Lichtman, M.D. Hematology & Oncology · Chapel Hill, NC
- John T. Mckay, D.O. Hematology & Oncology · Winston Salem, NC
- Kailash Mosalpuria, M.D., MPH Hematology & Oncology · Lincoln, NE
- Neha Korde, MD Internal Medicine · New York, NY
- Cesar Rodriguez Valdes, M.D. Medical Oncology · New York, NY
- Edward A. Faber JR., D.O., M.S. Hematology & Oncology · Cincinnati, OH
- Christopher A. Yasenchak, M.D. Hematology & Oncology · Eugene, OR
- Jason M. Melear, M.D. Medical Oncology · Austin, TX
- Habte A. Yimer IV, M.D. Hematology & Oncology · Tyler, TX
- Mitul Gandhi, M.D. Hematology & Oncology · Manassas, VA
- Rahul Banerjee, M.D. Hematology & Oncology · Seattle, WA
- Jorge M. Chaves, M.D. Hematology & Oncology · Tacoma, WA
- Danai Dima, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of North Carolina $371,074
- Mayo Clinic Hospital, AZ $233,934
- Mayo Clinic Rochester $199,050
- Northwest Medical Specialties $124,087
- Vanderbilt University Medical Center, TN $119,702
- Biomedical Research Alliance Of $107,837
- Texas Oncology - Northeast Texas $98,561
- University of Cincinnati $97,212
- Highlands Oncology Group PA $95,290
- University of Washington Medical Ctr, WA $94,151
- Virginia Cancer Specialists - Fairfax $93,726
- Rocky Mountain Cancer Centers - Aurora $87,607
- Nho Revive Research Institute LLC $80,382
- Fort Wayne Medical Oncology & Hemat $77,795
- Memorial Sloan-Kettering Cancer Ctr $74,644
- Hope and Healing Cancer Services L $64,572
- Wake Forest University $60,696
- The Administrators of the Tulane $53,922
- Willamette Valley Cancer Institute and Research Center $18,500
- Texas Oncology - Centralsouth Texas $4,070
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.